MarketResearchReports.Biz: Companion Diagnostics Market (Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma And Others) - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019 - New Industry Report
Market share analysis of the leading players operating in the companion diagnostics market, in terms of % share for the year 2012, has been presented in the competitive landscape. The report also includes the list of recommendations for new market entrants. Some of the key market players profiled in this report include Roche Holdings AG, Abbott Laboratories, Genomic Health, Inc., Qiagen N.V., Life Technologies Corporation, Agilent Technologies, Inc. and GE Healthcare, Ltd.
The global companion diagnostics market is segmented into the following categories:
Companion Diagnostics Market, by Indications
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Gastric Cancer
- Other (HIV, Thalassemia)
Companion Diagnostics Market, by Geography
- North America
- Rest of the World (RoW)
TO Read the complete Report with TOC @: http://www.marketresearchreports.biz/analysis/138982
Table of Contents
Chapter 1 Introduction
1.1 Report Description
1.2 Research Methodology
1.3 Market Segmentation
1.4 List Of Abbreviations
Chapter 2 Executive Summary
Chapter 3 Market Overview
3.2 Market Drivers
3.2.1 Rising Need For Companion Diagnostics Along With Targeted Therapies
3.2.2 Increasing Demand As Well As Developmental Efforts Towards Personalized Medicine
3.2.3 The Pharmacoeconomic Advantage: Reduced Drug Development Costs
3.2.4 Increasing Cancer Incidence Worldwide
3.2.5 Impact Analysis Of Ma
Page: 1 2 3 4 5 6 7 Related biology technology :1
Copyright©2012 PR Newswire.
All rights reserved
. Companion Diagnostics Market is Expected to Reach USD 5.6 Billion Globally in 2019: Transparency Market Research2
. Personalized Medicine Makes Its Way to Pets With Cancer: Morphogenesis and SEVO-Med Team up for a Canine Cancer Field Study, First of Its Kind, Side-Effect-Free Process to Treat Companion Animals3
. Life Technologies to Collaborate with Merck Serono for Companion Diagnostics Development and Commercialization4
. Medical Design Excellence Awards Selects Companion 2 Hospital Driver for Powering SynCardia Total Artificial Heart as Silver Winner5
. Empire Genomics Awarded SBIR Phase I Grant from NCI for Companion Diagnostics for Multiple Myeloma6
. Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer7
. Market Access Expert Firm, PRMA Consulting, Launches Companion Diagnostics Handbook8
. PrimeraDx to Co-Develop Companion Diagnostics with Quest Diagnostics9
. Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies10
. QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies11
. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
(Date:1/14/2014)... 2014 Date: Friday, April 11, 2014 ... Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... national nonprofit organization solely dedicated to finding a cure ... for those affected worldwide, will host its annual Crystal ... in Warrington, Pa. , Each year, the Crystal ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... has initiated coverage of Alliqua, Inc. (OTCQB: ALQA). ... manufacturing, and marketing proprietary products to serve the ... http://equitiesiq.com/reports/alliqua/ , In late 2012, Alliqua was ... which launched the company’s new strategy to become ...
(Date:1/14/2014)... , Jan. 14, 2014 RXi Pharmaceuticals ... on discovering, developing and commercializing innovative therapies ... technologies, today announced that it received the ... Patent and Trademark Office on its unique ... of fibrosis. The patent covers the use ...
(Date:1/14/2014)... 2014 During the 1600’s through the ... as “The Doctor’s Plague.” In this time period, doctors ... hands. This led, at times, to the death of ... hospital staff today don’t know that they may be ... explains. , A study showed that severe fatigue contributed ... Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... Mirus Bio Corp. , a Madison-based biotechnology firm, has ... U.S., that covers a method of treating patients with muscle ... ,The patent, titled "Intravascular Delivery of Nucleic Acid," covers a ... to body tissues via the blood stream and compliments a ...
... to a venture capitalist who could invest millions in your ... yet. , ,You have 90 seconds to explain, starting now. ... yearly event at the Wisconsin Early-Stage Symposium . This ... a few hard knocks to hopeful entrepreneurs who presented their ...
... to paraphrase Sally Field - "You like us, you really like ... a keen observation: that some of the companies debuted "features" rather ... the technologies on the DEMO stage. Yet I suspect there was ... does not a company make. Or perhaps I should say "not ...Cached Biology Technology:Mirus granted European patent for gene therapy 29 tips for making 90 seconds count in an investment pitch 2Sometimes, features can make a company 2Sometimes, features can make a company 3
Blank Calibration Particles, 3.0-3.4 mu m 5 ml...
b-Catenin (pSer675), phospho-specific...
BDFastImmune? IFN-gamma /CD69/CD4/CD3 Storage Temperature: Refrigerate(2 to 8C)...
PKC (pSer345), phospho-specific...Biology Products: